Anzeige
+++Kupfer-Junior startet Bohrung: Ramp Metals stieg von 0,15 auf 1,80 CAD – zieht dieser Nachbar jetzt nach? Ramp Metals stieg von 0,15 auf 1,80 CAD – zieht dieser Nachbar jetzt nach?+++
EQS-News

MGI Tech Brings High-Throughput T7+ Sequencer to European Market at Analytica 2026 Debut 25.03.2026, 11:10 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: MGI Tech Co., Ltd. / Key word(s): Miscellaneous
MGI Tech Brings High-Throughput T7+ Sequencer to European Market at Analytica 2026 Debut

25.03.2026 / 11:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


MUNICH, March 25, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is showcasing cutting-edge automation and sequencing technologies at the Analytica 2026 in Munich, Germany. Making its first appearance at the trade fair, MGI is featuring advanced sequencing and automation platforms, including the new high-throughput sequencer T7+, now available to customers in Europe and Africa, and the automation workstation PrepAll, designed to revolutionize liquid handling in laboratories around Europe.

Bringing High-Throughput Sequencing to European Labs

MGI introduced the T7+, making its global debut in September 2025 during the Future of Omics conference in Shenzhen, China. The company now makes this high-throughput sequencing platform available to customers in Europe and Africa, enabling users to process up to 112 WGS or 80 Single cell RNA-seq or 1,920 RNA-seq in one run, based on the actual operation feedback from the client. This marks the first time the full-size instrument is being shown to the European audience.

MGI's T7+ sequencing platform is fully agnostic and designed to reduce hands-on time through integrated workflow automation, while allowing users to retain their existing pipelines, tools, and data strategy.

T7+ sequencer at Analytica 2026

Fang Chen, General Manager of Europe & Africa at MGI confirmed that over 40 units are installed globally since its launch and it is time to ensure customers in Europe and Africa can benefit from its performance, which integrates several steps which previously needed manual intervention.

Intelligent Automation for Labs of All Sizes

In addition, the company is exhibiting its automation platform PrepAll, which was first presented during the SLAS in Hamburg in 2025 and is now commercially available globally. The intelligent liquid handler combines key features from other MGI automation platforms in a compact design, enabling the smallest laboratories to adapt automation for their pipetting workflow.

"It is our first time exhibiting during the Analytica, and I am thrilled to present our latest innovations to the broader European community," said Fang Chen, General Manager of Europe & Africa at MGI. "We're invigorated by the diverse audience from different segments gathered here to improve their laboratory workflow solutions. Our robust sequencing technology and sophisticated automation technology is just the start, and we intend to use this trade fair in the future to provide researchers and clinical laboratories with a breath of equipment."

Visit MGI at Analytica 2026: Hall A3, Booth 317 to experience live demonstrations of the T7+ and PrepAll, and to learn more about MGI's full sequencing and automation portfolio.

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

To learn more, please visit MGI TechLinkedInX, Instagram, and YouTube.

Photo - https://mma.prnewswire.com/media/2942046/T7__sequencer_at_MGI_booth.jpg

Cision View original content:https://www.prnewswire.com/de/pressemitteilungen/mgi-tech-brings-high-throughput-t7-sequencer-to-european-market-at-analytica-2026-debut-302724692.html

rt.gif?NewsItemId=EN18940&Transmission_Id=202603250542PR_NEWS_EURO_ND__EN18940&DateId=20260325


25.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2297618  25.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer